Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperkalaemia Clear all
Completed No phase listed Observational Results available

POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study

NCT02609841
View directory record Official record
Conditions
Hyperkalemia
Interventions
Cardiac rhythm remote monitoring system
Device
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • San Jose, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

NCT05535920
View directory record Official record
Conditions
Hyperkalemia
Interventions
LOKELMA 5 GM Powder for Oral Suspension
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
La Jolla, California • Lawrenceville, Georgia • Fort Wayne, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Early Protein Supplementation on Prevention of Hyperkalemia

NCT00290160
View directory record Official record
Conditions
Hyperkalemia
Interventions
Protein supplementation
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
1 Minute to 12 Hours
Enrollment
62 participants
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

NCT01737697
View directory record Official record
Conditions
Hyperkalemia
Interventions
Zirconium silicate (acute phase), Zirconium silicate (subacute phase), Placebo (acute phase), Placebo ( subacute phase)
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Anniston, Alabama • Huntsville, Alabama • Glendale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

NCT03229265
View directory record Official record
Conditions
Hyperkalemia, Kidney Transplant
Interventions
Patiromer
Drug
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

NCT02107092
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsboro, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

NCT05056727
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Phase 2 Interventional

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

NCT05766839
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
0 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

NCT02933450
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Patiromer 25.2 g
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Potassium Binders in the ER

NCT04585542
View directory record Official record
Conditions
Acute Hyperkalemia, Oral Potassium Binders
Interventions
Polyethylene Glycol 3350, Sodium Polystyrene Sulfonate Oral Suspension [SPS], Patiromer, Sodium zirconium cyclosilicate
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Phase 1Phase 2 Interventional

Adding Urea to the Final Dialysis Fluid

NCT06366230
View directory record Official record
Conditions
Dysequilibrium Syndrome, ESRD, Hyperkalemia, Metabolic Acidosis
Interventions
Urea in the dialysate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

NCT02483702
View directory record Official record
Conditions
Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions
Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
2 Months to 6 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

NCT04676646
View directory record Official record
Conditions
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicate, Placebo, Spironolactone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting No phase listed Observational

AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring

NCT07210021
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
Interventions
AK+ Guard™ ECG Application
Device
Lead sponsor
AccurKardia, Inc.
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

NCT04727528
View directory record Official record
Conditions
Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Florence, Alabama • Chula Vista, California • Downey, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

NCT06343129
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Dietary education program
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

NCT02088073
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsboro, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 4 Interventional Results available

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On

NCT03597035
View directory record Official record
Conditions
Type2 Diabetes, Hyperkalemia
Interventions
Spironolactone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG)

NCT05441852
View directory record Official record
Conditions
Hyperkalemia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 89 Years
Enrollment
1,151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 4 Interventional

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

NCT04443608
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer Powder for Oral Suspension [Veltassa], Placebo
Drug
Lead sponsor
Comprehensive Research Associates
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

NCT02163499
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Scottsboro, Alabama • Tempe, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Spironolactone for Reducing Proteinuria in Diabetic Nephropathy

NCT00498537
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
spironolactone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.

NCT03303521
View directory record Official record
Conditions
Hyperkalemia
Interventions
Placebo, Sodium Zirconium Cyclosilicate (ZS)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Los Angeles, California • Ontario, California • San Dimas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 11, 2026, 10:25 PM EDT